NMC
TRVI icon

NEA Management Company’s Trevi Therapeutics TRVI Stock Holding History

NEA Management Company’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$247M Hold
13,222,228
– – 15.53% 1
2026
Q1 		$158M Hold
13,222,228
– – 8.97% 4
2025
Q4 		$166M Hold
13,222,228
– – 8.44% 4
2025
Q3 		$121M Hold
13,222,228
– – 6.64% 5
2025
Q2 		$72.3M Buy
13,222,228
+1,851,852
+16% +$11.5M 5.44% 6
2025
Q1 		$71.5M Hold
11,370,376
– – 5.51% 6
2024
Q4 		$48.8M Hold
11,370,376
– – 2.76% 11
2024
Q3 		$38M Hold
11,370,376
– – 2.07% 12
2024
Q2 		$33.9M Hold
11,370,376
– – 2.55% 10
2024
Q1 		$39.2M Hold
11,370,376
– – 2.44% 12
2023
Q4 		$15.2M Hold
11,370,376
– – 1.02% 20
2023
Q3 		$24.8M Hold
11,370,376
– – 1.91% 16
2023
Q2 		$27.2M Hold
11,370,376
– – 2.07% 16
2023
Q1 		$21M Sell
11,370,376
-2,798
-0% -$6.33K 1.45% 20
2022
Q4 		$22M Hold
11,373,174
– – 1.23% 22
2022
Q3 		$17.5M Hold
11,373,174
– – 0.87% 30
2022
Q2 		$32M Buy
11,373,174
+11,370,376
+406,375% +$27.9M 1.64% 14
2022
Q1 		$17.1M Sell
2,798
-5,937,998
-100% -$6.15M 0.5% 29
2021
Q4 		$4.63M Hold
5,940,796
– – 0.09% 52
2021
Q3 		$8.32M Hold
5,940,796
– – 0.1% 53
2021
Q2 		$13.4M Hold
5,940,796
– – 0.17% 50
2021
Q1 		$16.1M Hold
5,940,796
– – 0.36% 44
2020
Q4 		$14.4M Hold
5,940,796
– – 0.38% 42
2020
Q3 		$23.9M Hold
5,940,796
– – 1.01% 25
2020
Q2 		$39.1M Buy
5,940,796
+1,499,436
+34% +$5.28M 1.57% 17
2020
Q1 		$14.6M Hold
4,441,360
– – 0.76% 22
2019
Q4 		$16.7M Hold
4,441,360
– – 0.79% 22
2019
Q3 		$20M Buy
4,441,360
+11,556
+0.3% +$62.8K 1.65% 19
2019
Q2 		$33.2M Buy
+4,429,804
New +$38.1M 2.33% 17

Other funds holding TRVI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

NEA Management Company's TRVI Position: Q2 2026 in Review

NEA Management Company held its Trevi Therapeutics (TRVI) position steady in Q2 2026 at 13,222,228 shares worth $247M. The position accounts for 15.53% of the portfolio, ranked #1.

NEA Management Company first reported a position in TRVI in Q2 2019 and has held it in 29 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • NEA Management Company held 13,222,228 shares of Trevi Therapeutics worth $247M as of Q2 2026.
  • NEA Management Company left its Trevi Therapeutics share count unchanged in Q2 2026.
  • Trevi Therapeutics made up 15.53% of NEA Management Company's portfolio in Q2 2026, its #1 holding.
  • NEA Management Company first reported a position in Trevi Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on NEA Management Company's 13F filing for Q2 2026, filed 14 Aug 2026.